Evaluating the Safety Profile of Alpha-1 Blockers, 5-Alpha-Reductase Inhibitors, and PDE5 Inhibitors for BPH: A Disproportionality Analysis of Real-World Adverse Events Based on FDA Adverse Event Reporting System
March 2026
in “
The Aging Male
”
Studysummary This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on tandfonline.com →